Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety
| Autor: | Betul Buyuktiryaki, Umit Murat Sahiner, Ozge Soyer, Melike Ocak, B. E. Sekerel |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Adolescent Immunology Omalizumab Immunoglobulin E 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Anti-Allergic Agents medicine Humans Immunology and Allergy Chronic Urticaria In patient Adverse effect Angioedema biology business.industry General Medicine Treatment Outcome 030228 respiratory system Concomitant biology.protein Female medicine.symptom Every Four Weeks business 030215 immunology medicine.drug |
| Zdroj: | Allergologia et Immunopathologia. 48:368-373 |
| ISSN: | 0301-0546 |
| DOI: | 10.1016/j.aller.2020.03.011 |
| Popis: | Background Omalizumab is useful as an add-on treatment in patients unresponsive to high doses of second-generation antihistamines. This study aimed to evaluate the efficacy and safety of omalizumab treatment in adolescents with refractory chronic spontaneous urticaria (CSU). Methods CSU patients aged 12–18 years old with the diagnosis of symptomatic CSU and unresponsive to classical treatment were included in the study. All patients had an urticaria-activity-score (UAS7) of ≥16 or and were treated with 300 mg omalizumab every four weeks. The degree of response was classified into complete, partial and non-responders due to UAS7. Results A total of 29 patients were evaluated. The median age and symptom onset age of the patients was 15.2 (IQR, 12.8–16.5) years and 14.0 (IQR, 11.8–15.9) years, respectively. The median duration of urticaria was eight (IQR, 4–24) months at admission. Eleven (37.9%) patients had angioedema and ten (34.5%) patients had concomitant allergic diseases. The median age at the beginning of treatment with omalizumab was 15.4 (IQR, 12.9–16.9) years. The median symptom duration was 12 (IQR, 6.5–27.5) months before the omalizumab treatment. Twenty-eight (96.5%) of the patients (89.6% complete, 6.9% partial) achieved response; however, one patient was a non-responder (3.5%). The adverse effect was observed in one (3.4%) patient as angioedema after the third dose. Twenty-three patients were followed up for a median of 18 (IQR, 13–27) months. Relapse was observed in three (13%) patients. Conclusions Omalizumab is considered as an effective and safe treatment for CSU in adolescents. Relapses mostly occur within the first year after the cessation of treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|